Herren Wu
Overview
Explore the profile of Herren Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
3883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyazaki T, Chen S, Florinas S, Igarashi K, Matsumoto Y, Yamasoba T, et al.
ACS Nano
. 2022 Aug;
16(8):12290-12304.
PMID: 35942986
Assessment of drug activation and subsequent interaction with targets in living tissues could guide nanomedicine design, but technologies enabling insight into how a drug reaches and binds its target are...
2.
Shan L, van Dyk N, Haskins N, Cook K, Rosenthal K, Mazor R, et al.
Commun Biol
. 2021 Sep;
4(1):1048.
PMID: 34497355
In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of...
3.
Allen K, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, et al.
PLoS One
. 2021 May;
16(5):e0252060.
PMID: 33999954
[This corrects the article DOI: 10.1371/journal.pone.0234268.].
4.
Mao S, Chaerkady R, Yu W, DAngelo G, Garcia A, Chen H, et al.
Mol Cancer Ther
. 2021 Mar;
20(3):541-552.
PMID: 33653945
Resistance to antibody-drug conjugates (ADCs) has been observed in both preclinical models and clinical studies. However, mechanisms of resistance to pyrrolobenzodiazepine (PBD)-conjugated ADCs have not been well characterized and thus,...
5.
Shan L, Cook K, Haskins N, Omar B, Jiang Y, Garcia A, et al.
Sci Rep
. 2020 Oct;
10(1):17257.
PMID: 33057063
Neuregulin protein 1 (NRG1) is a large (> 60-amino-acid) natural peptide ligand for the ErbB protein family members HER3 and HER4. We developed an agonistic antibody modality, termed antibody ligand...
6.
Urello M, Xiang L, Colombo R, Ma A, Joseph A, Boyd J, et al.
Biomacromolecules
. 2020 Aug;
21(9):3596-3607.
PMID: 32786528
Synthetic gene delivery systems employ multiple functions to enable safe and effective transport of DNA to target cells. Here, we describe metabolite-based poly(l-lysine) (PLL) modifiers that improve transfection by imparting...
7.
Allen K, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, et al.
PLoS One
. 2020 Jun;
15(6):e0234268.
PMID: 32497150
Annexin A1 (anxA1) is an immunomodulatory protein that has been proposed as a tumor vascular target for antitumor biologic agents, yet to date the vascular expression of anxA1 in specific...
8.
Li Q, Chan C, Peterson N, Hanna R, Alfaro A, Allen K, et al.
ACS Chem Biol
. 2020 Mar;
15(4):830-836.
PMID: 32155049
Efficacious use of therapeutic gene delivery via nanoparticles is hampered by the challenges associated with targeted delivery to tissues of interest. Systemic administration of lipid nanoparticle (LNP)-encapsulated mRNA leads to...
9.
Steinhardt J, Wu Y, Fleming R, Ruddle B, Patel P, Wu H, et al.
Pharmaceutics
. 2019 Dec;
12(1).
PMID: 31861347
Bispecific antibody (bsAb) applications have exponentially expanded with the advent of molecular engineering strategies that have addressed many of the initial challenges, including improper light chain pairing, heterodimer purity, aggregation,...
10.
Li Q, Peterson N, Hanna R, Kuszpit K, White J, Allen K, et al.
Mol Pharm
. 2019 Dec;
17(2):507-516.
PMID: 31841002
Targeted strategies to deliver and retain drugs to kidneys are needed to improve drug accumulation and efficacy in a myriad of kidney diseases. These drug delivery systems show potential for...